HER2-Negative Breast Cancer Market Report 2026

HER2-Negative Breast Cancer Market Overview

• HER2-Negative Breast Cancer market size has reached to $17.57 billion in 2025 • Expected to grow to $25.41 billion in 2030 at a compound annual growth rate (CAGR) of 7.6% • Growth Driver: Rising Breast Cancer Incidence Drives Growth Of The Market • Market Trend: Regulatory Approvals And Market Expansion In HER2-Negative Breast Cancer Treatments • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under HER2-Negative Breast Cancer Market?

HER2-negative breast cancer refers to a type of breast cancer where the cancer cells do not have high levels of the HER2 protein, which promotes tumour growth. This type of cancer tends to grow more slowly than HER2-positive breast cancer and is treated with targeted therapies and chemotherapy. The main treatment types of HER2-negative breast cancer are chemotherapy, hormone therapy, targeted therapy, and immunotherapy. Chemotherapy refers to a type of cancer treatment that uses powerful drugs to kill or inhibit the growth of cancer cells by targeting and destroying rapidly dividing cells in the body. It includes different stages, including early stage, locally advanced stage, and metastatic stage, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The HER2-Negative Breast Cancer Market Growth Forecast?

The her2-negative breast cancer market size is expected to see strong growth in the next few years. It will grow to $25.41 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing demand for personalized oncology treatments, rising adoption of genomic-driven therapies, expansion of immunotherapy pipelines, growing focus on improving progression-free survival, increasing investment in oncology drug development. Major trends in the forecast period include increasing adoption of personalized hormone therapy regimens, growing use of cdk4/6 inhibitors, expansion of genomic testing for treatment selection, rising integration of immunotherapy in advanced stages, enhanced focus on combination treatment protocols.

Global HER2-Negative Breast Cancer Market Segmentation

1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy 2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites 2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs) 3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors 4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy

What Is The Driver Of The HER2-Negative Breast Cancer Market?

Rising incidence of breast cancer cases is expected to propel the growth of the HER2-negative breast cancer market going forward. Breast cancer is a disease characterized by the uncontrolled growth of abnormal cells in the breast tissue, commonly originating in the ducts or lobules. The rising incidence of breast cancer cases can be attributed to several factors, including increased awareness and improved screening methods, leading to earlier and more frequent detection. HER2-Negative Breast Cancer plays a crucial role in advancing breast cancer research by providing insights into distinct tumor biology and treatment strategies, contributing to the development of more targeted therapies for patients. For instance, in 2025, according to the American Cancer Society, a US-based professional organization company, in 2025, the United States is projected to see approximately 316,950 new cases of invasive breast cancer in women and 2,800 cases in men, along with an estimated 59,080 cases of ductal carcinoma in situ (DCIS) diagnosed in women. Therefore, the rising incidence of breast cancer cases is driving the growth of the HER2-negative breast cancer industry.

Key Players In The Global HER2-Negative Breast Cancer Market

Major companies operating in the her2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

Global HER2-Negative Breast Cancer Market Trends and Insights

Major companies operating in the HER2-negative breast cancer market are focusing on securing regulatory approvals to introduce new treatments, expand their product portfolios, and enhance their market presence. Regulatory approvals refer to the official authorization granted by government agencies, allowing companies to market and distribute drugs or treatments after meeting safety, efficacy, and quality standards. For instance, in October 2024, Genentech Inc., a US-based biotechnology corporation, received FDA approval for Itovebi (inavolisib) as a targeted treatment for advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This approval allows Itovebi to be used in combination with palbociclib and fulvestrant, significantly improving progression-free survival for patients compared to standard treatments. This new regimen provides a vital option for patients facing limited treatment choices, emphasizing the importance of biomarker testing to identify those who would benefit most from this therapy.

What Are Latest Mergers And Acquisitions In The HER2-Negative Breast Cancer Market?

In June 2024, Relay Therapeutics Inc., a US-based clinical-stage precision medicine company, collaborated with Pfizer Inc. This collaboration is aimed at evaluating atirimociclib, Pfizer’s investigative selective CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer. This collaboration also aims to leverage the unique properties of both drugs to minimize off-target toxicity that has limited the efficacy of non-selective agents in the past. Pfizer Inc. is a US-based pharmaceutical and biotechnology corporation actively involved in the treatment of HER2-negative breast cancer.

Regional Outlook

North America was the largest region in the HER2-negative breast cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the HER2-Negative Breast Cancer Market?

The HER2-negative breast cancer market includes revenues earned by entities by providing services such as radiation therapy, genetic testing, mammography, and counseling and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the HER2-Negative Breast Cancer Market Report 2026?

The her2-negative breast cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the her2-negative breast cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.